Kelly Rauber

Human Resources Officer at VERA THERAPEUTICS, INC.

Health Technology

Consumer Services

Profile

Kelly Rauber is currently the Vice President & Head-Human Resources at Vera Therapeutics, Inc. Prior to this, Ms. Rauber held positions as the Senior Director-Human Resources at Dermira, Inc., Orchard Therapeutics Plc, and Oric Pharmaceuticals, Inc. Ms. Rauber completed their undergraduate degree at Santa Clara University.

Kelly Rauber active positions

Companies	Position	Start
VERA THERAPEUTICS, INC.	Human Resources Officer	2022-09-30

All active positions of Kelly Rauber

Former positions of Kelly Rauber

Companies	Position	End
DERMIRA, INC.	Human Resources Officer	-
ORCHARD THERAPEUTICS PLC	Human Resources Officer	-
ORIC PHARMACEUTICALS, INC.	Human Resources Officer	-

See the detail of Kelly Rauber's experience

Training of Kelly Rauber

Santa Clara University

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Kelly Rauber's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
ORIC PHARMACEUTICALS, INC.	Health Technology
VERA THERAPEUTICS, INC.	Health Technology

Private companies	2
Dermira, Inc. Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN.	Health Technology
Orchard Therapeutics Plc Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.	Health Technology